Welcome to our dedicated page for UBS ETRACS Alerian MLP Index ETN Series B SEC filings (Ticker: AMUB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The ETRACS Alerian MLP Index ETN Series B due July 18, 2042 (AMUB) is issued by UBS AG, a foreign private issuer that reports to the US Securities and Exchange Commission. UBS AG indicates that it files a registration statement on Form F-3, including a prospectus and supplements, for offerings of securities related to ETRACS ETNs such as AMUB. These documents set out the terms of the ETN and include a "Risk Factors" section that UBS urges investors to review before investing.
UBS AG also submits annual reports on Form 20-F and periodic reports on Form 6-K. In its Form 6-K filings, UBS provides information on capitalization, total debt issued, equity and other capital and liquidity metrics, as well as updates on regulatory developments and other corporate matters. UBS AG notes that its consolidated financial statements are prepared in accordance with IFRS Accounting Standards, and that certain 6-K reports are incorporated by reference into its Form F-3 registration statement.
For AMUB, the relevant SEC filings include the base prospectus, prospectus supplements and any pricing supplements that describe the specific terms of the ETRACS Alerian MLP Index ETN Series B. UBS’s public materials state that these offering documents are available through the SEC’s EDGAR system. They also clarify that the securities related to the offerings are not deposit liabilities and are not insured or guaranteed by the Federal Deposit Insurance Corporation or any other governmental agency of the United States, Switzerland or any other jurisdiction.
On this page, users can access AMUB-related SEC filings and associated issuer reports. The platform provides real-time updates from EDGAR and AI-powered summaries that explain the key points of lengthy documents, such as registration statements, prospectus supplements and UBS AG’s periodic reports. This allows investors to quickly identify disclosures that affect AMUB, including risk factor updates, capital and funding information, and other details relevant to UBS AG’s role as issuer of this senior unsecured ETN.
UBS AG is offering Trigger Autocallable Contingent Yield Notes linked to the common stock of CrowdStrike Holdings, Inc., maturing on or about October 18, 2027. The Notes pay contingent coupons only if the underlying’s closing level on an observation date is at or above a coupon barrier, and they may be automatically called if the underlying closes at or above the initial level on any observation date before the final valuation date.
If not called, principal is repaid at maturity only if the final level is at or above the downside threshold; otherwise, repayment is reduced in line with the underlying’s decline, and you could lose all of your investment. All payments are subject to the creditworthiness of UBS.
The Notes will not be listed. The expected trade date is October 14, 2025; final valuation is October 14, 2027. Minimum investment is 100 Notes at $10 per Note. The estimated initial value is expected to be between $9.54 and $9.79 per Note. Initial delivery is T+2; secondary trades generally settle T+1 unless otherwise arranged.
UBS AG is offering $881,000 of Buffer Callable Contingent Yield Notes linked to the least performing of the Russell 2000 Index and the S&P 500 Index, due October 13, 2028. The notes pay a 9.20% per annum contingent coupon only when both indices close at or above their coupon barriers on observation dates.
UBS may call the notes quarterly after 12 months; if called, holders receive principal plus any due coupon on the call settlement date. If not called, principal is repaid at maturity only if each index finishes at or above its downside threshold, set at 85% of the initial level (a 15% buffer). If any index finishes below its threshold, repayment is reduced by the decline beyond the buffer, based on the worst performer, and losses could be substantial.
Economics per note: issue price $1,000, underwriting discount $5, proceeds to UBS $995, and estimated initial value $974. Key dates include a trade date of October 10, 2025, monthly coupon observations, quarterly call dates (after 12 months), and maturity on October 13, 2028. Payments depend on UBS’s credit.